OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
Panpan Zhang, Si Shi, Jianming Xu, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113539-113539
Open Access | Times Cited: 9
Panpan Zhang, Si Shi, Jianming Xu, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113539-113539
Open Access | Times Cited: 9
Showing 9 citing articles:
Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment
Baizhou Tan, Beiyu Zhang, Hongping Chen
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 4
Baizhou Tan, Beiyu Zhang, Hongping Chen
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 4
Insights into CSF-1/CSF-1R signaling: the role of macrophage in radiotherapy
Qingchao Shang, Pei Zhang, Lei Xiao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Qingchao Shang, Pei Zhang, Lei Xiao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET )
Michael A. Morse, Erika J. Crosby, Daniel M. Halperin, et al.
Journal of Neuroendocrinology (2025)
Closed Access
Michael A. Morse, Erika J. Crosby, Daniel M. Halperin, et al.
Journal of Neuroendocrinology (2025)
Closed Access
Liver Transplantation for Non-Hepatocellular Carcinoma: Role of Immune Checkpoint Inhibitors
Pegah Bahrami, Mohammad Al Zein, Ali H. Eid, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102558-102558
Closed Access
Pegah Bahrami, Mohammad Al Zein, Ali H. Eid, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102558-102558
Closed Access
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis
Sophie Cousin, Jean‐Philippe Guégan, Lola‐Jade Palmieri, et al.
Nature Cancer (2025)
Closed Access
Sophie Cousin, Jean‐Philippe Guégan, Lola‐Jade Palmieri, et al.
Nature Cancer (2025)
Closed Access
The prognostic impact of surufatinib for the treatment of advanced pancreatic ductal adenocarcinoma: a single center real-world retrospective study
Yanzhen Yang, Qu Xie, Congcong Shang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Yanzhen Yang, Qu Xie, Congcong Shang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Blood levels of zearalenone, thyroid-stimulating hormone, and thyroid hormones in patients with colorectal cancer
Sylwia Lisieska-Żołnierczyk, Magdalena Gajęcka, Łukasz Zielonka, et al.
Toxicon (2024) Vol. 251, pp. 108125-108125
Open Access | Times Cited: 1
Sylwia Lisieska-Żołnierczyk, Magdalena Gajęcka, Łukasz Zielonka, et al.
Toxicon (2024) Vol. 251, pp. 108125-108125
Open Access | Times Cited: 1
Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population
Yuanyuan Liu, Xinyi Yang, Yan Wang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Yuanyuan Liu, Xinyi Yang, Yan Wang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas
T. Pavlidis, I. Galanis, T. Pavlidis
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 12, pp. 4559-4564
Closed Access
T. Pavlidis, I. Galanis, T. Pavlidis
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 12, pp. 4559-4564
Closed Access
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors
Pascal Hammel, Denis Smith, Pauline Afchain, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Pascal Hammel, Denis Smith, Pauline Afchain, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
